SG11201809223PA - Erbb inhibitors and uses thereof - Google Patents

Erbb inhibitors and uses thereof

Info

Publication number
SG11201809223PA
SG11201809223PA SG11201809223PA SG11201809223PA SG11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA
Authority
SG
Singapore
Prior art keywords
international
pct
ell
english
april
Prior art date
Application number
SG11201809223PA
Other languages
English (en)
Inventor
Christopher Novotny
Kevan Shokat
Weijun Shen
Original Assignee
Univ California
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Scripps Research Inst filed Critical Univ California
Publication of SG11201809223PA publication Critical patent/SG11201809223PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Drilling Tools (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG11201809223PA 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof SG11201809223PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324864P 2016-04-19 2016-04-19
PCT/US2017/028437 WO2017184775A1 (en) 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
SG11201809223PA true SG11201809223PA (en) 2018-11-29

Family

ID=60116344

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809223PA SG11201809223PA (en) 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof

Country Status (13)

Country Link
US (1) US20190119284A1 (ja)
EP (1) EP3445768A4 (ja)
JP (1) JP2019514869A (ja)
CN (1) CN109952306A (ja)
AU (1) AU2017253096A1 (ja)
BR (1) BR112018071592A8 (ja)
CA (1) CA3021324A1 (ja)
EA (1) EA201892368A1 (ja)
IL (1) IL262400A (ja)
MX (1) MX2018012797A (ja)
PH (1) PH12018502233A1 (ja)
SG (1) SG11201809223PA (ja)
WO (1) WO2017184775A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082A (zh) * 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗
US20210347785A1 (en) * 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
AU2020206640B2 (en) * 2019-01-11 2022-09-08 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound or salt thereof
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
CN111303158A (zh) * 2020-04-09 2020-06-19 成都睿智化学研究有限公司 一种(4-氯-1H-吡唑啉[3,4-d]嘧啶-3-基)芳基甲酮的制备方法
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
AU711592B2 (en) * 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP4881875B2 (ja) * 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
JP2010523712A (ja) * 2007-04-13 2010-07-15 スーパージェン, インコーポレイテッド 癌または過剰増殖の治療に有用なaxlキナーゼ阻害剤
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
TW201107328A (en) * 2009-07-28 2011-03-01 Daiichi Sankyo Co Ltd Pyrrolo [2,3-d] pyrimidine derivatives
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途

Also Published As

Publication number Publication date
IL262400A (en) 2018-12-31
BR112018071592A8 (pt) 2019-02-26
MX2018012797A (es) 2020-01-09
CA3021324A1 (en) 2017-10-26
WO2017184775A1 (en) 2017-10-26
PH12018502233A1 (en) 2019-06-03
US20190119284A1 (en) 2019-04-25
EA201892368A1 (ru) 2019-05-31
BR112018071592A2 (pt) 2019-02-12
EP3445768A4 (en) 2019-12-18
EP3445768A1 (en) 2019-02-27
JP2019514869A (ja) 2019-06-06
CN109952306A (zh) 2019-06-28
AU2017253096A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
SG11201809223PA (en) Erbb inhibitors and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201808990QA (en) Compositions for topical application of compounds
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201811074RA (en) Nant cancer vaccine
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same